Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy

Published:2021-05-13 Issue:8 Volume:21 Page:809-817
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Bronte Giuseppe¹,Cafaro Alessandro²,Pasini Luigi³,Priano Ilaria¹,Andrikou Kalliopi¹,Cravero Paola¹,Burgio Marco Angelo¹,Delmonte Angelo¹,Crinò Lucio¹

Affiliation:

1. Department of Medical Oncology, IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

2. Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

3. Biosciences Laboratory, IRCCS Istituto Romagnolo per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

Funder

no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2021.1923485

Reference40 articles.

1. Oncogene-addicted non-small cell lung cancer and immunotherapy

2. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

3. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer

4. Anaplastic lymphoma kinase: signalling in development and disease

5. Treating ALK-positive lung cancer—early successes and future challenges

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study;Cancers;2022-03-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3